Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension

Yohei Miura, Masaharu Kataoka, Tomohiro Chiba, Takumi Inami, Hideaki Yoshino, Toru Satoh

Research output: Contribution to journalArticle


Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

Original languageEnglish
Pages (from-to)2676-2677
Number of pages2
JournalCirculation Journal
Issue number10
Publication statusPublished - 2018 Jan 1



  • Epoprostenol
  • Giant fold gastritis
  • Pulmonary arterial hypertension
  • Stomach barium examination

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this